Drug intelligence / Profile preview

ST-1703

Development stage: Unknown
Lead developer: Beijing Scitech-Mq Pharmaceuticals
Modality: Small Molecules

Overview

ST-1703 is a small-molecule dual inhibitor of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2). Developed by Beijing Scitech-Mq Pharmaceuticals, it is designed to treat HER2-positive solid tumors, including breast cancer, gastric cancer, and non-small cell lung cancer (NSCLC). A key therapeutic focus for ST-1703 is its potential efficacy against brain metastases, which are common in advanced HER2-positive cancers. The drug is currently in Phase 2 clinical development, aiming to provide a targeted treatment option for patients with advanced malignancies that overexpress these receptors.

Targets

EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on ST-1703.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST-1703.

Explore the full profile